“Low-Risk” Prediction Rule for Pediatric Oncology Patients Presenting With Fever and Neutropenia

作者: Robert J. Klaassen , T. Robin Goodman , Ba Pham , John J. Doyle

DOI: 10.1200/JCO.2000.18.5.1012

关键词:

摘要: PURPOSE: To prospectively derive and validate a clinical prediction rule to allow more tailored approach the management of pediatric oncology outpatients presenting with fever neutropenia. PATIENTS AND METHODS: The was derived over 1-year period then validated following 8 months in new set neutropenia episodes. Patients were excluded if they presented comorbidity or an abnormal chest x-ray (CXR). RESULTS: Significant bacterial infection (SBI; defined as any blood urine culture positive for bacteria, interstitial lobar consolidation on CXR, unexpected death from infection) documented 43 227 Multivariate analysis found four significant factors: bone marrow disease, general appearance unwell initial examination, monocyte count less than 0.1 × 109/L, peak oral equivalent temperature greater 39°C. Only contributed determining low-risk group, excluding SBI 84% se...

参考文章(26)
Imtiaz A. Malik, Wajahat A. Khan, Michele Karim, Zeba Aziz, M. Ata Khan, Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial The American Journal of Medicine. ,vol. 98, pp. 224- 231 ,(1995) , 10.1016/S0002-9343(99)80367-2
Gary R. Jones, Gwen K. Konsler, Rose P. Dunaway, Stuart H. Gold, Herbert A. Cooper, Robert J. Wells, Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition The Journal of Pediatrics. ,vol. 124, pp. 703- 708 ,(1994) , 10.1016/S0022-3476(05)81358-7
John J Doyle, Susan M King, Stephen A Comay, Melvin H Freedman, ORAL ANTIBIOTIC THERAPY FOR “LOW RISK” FEBRILE NEUTROPENIC EPISODES (FNE). † 912 Pediatric Research. ,vol. 39, pp. 154- 154 ,(1996) , 10.1203/00006450-199604001-00934
J A Talcott, R D Siegel, R Finberg, L Goldman, Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. Journal of Clinical Oncology. ,vol. 10, pp. 316- 322 ,(1992) , 10.1200/JCO.1992.10.2.316
I. A. Malik, W. A. Khan, Z. Aziz, M. Karim, Self-Administered Antibiotic Therapy for Chemotherapy-Induced, Low-Risk Febrile Neutropenia in Patients with Nonhematologic Neoplasms Clinical Infectious Diseases. ,vol. 19, pp. 522- 527 ,(1994) , 10.1093/CLINIDS/19.3.522
P. A. Pizzo, D. Armstrong, G. Bodey, B. d. Pauw, R. Feld, M. Glauser, H. Gaya, J. Karp, J. Klastersky, G. Todeschini, J. Verhoef, J. Wade, L. S. Young, J. Remington, From the Immunocompromised Host Society: The Design, Analysis, and Reporting of Clinical Trials on the Empirical Antibiotic Management of the Neutropenic Patient: Report of a Consensus Panel The Journal of Infectious Diseases. ,vol. 161, pp. 397- 401 ,(1990) , 10.1093/INFDIS/161.3.397
Ching-Hon Pui, James M. Boyett, Walter T. Hughes, Gaston K. Rivera, Michael L. Hancock, John T. Sandlund, Timothy Synold, Mary V. Relling, Raul C. Ribeiro, William M. Crist, William E. Evans, Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia The New England Journal of Medicine. ,vol. 336, pp. 1781- 1787 ,(1997) , 10.1056/NEJM199706193362503
O. C. Tablan, Recommendations for preventing the spread of vancomycin resistance Infection Control and Hospital Epidemiology. ,vol. 16, pp. 105- 113 ,(1995)